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OBJECTIVE: To evaluate the relative occurrence of amputations
for diabetic foot ulcer (DFU) patients treated with negative pres-
sure wound therapy (NPWT), as delivered by Vacuum-Assisted
Closure Therapy, compared to patients treated with traditional
wound therapies (control group) in two different patient popu-
lations. METHODS: A retrospective database analysis using
administrative data from two different sources was completed.
Data sources included: 1) a commercial payor source including
2002–2003 claims and 2) a random 5% sample of 2003
Medicare claims (CMS). ICD-9-CM diagnosis and procedure
codes, CPT-4 and HCPCS codes were used to identify NPWT
and control patients. Risk adjustment procedures were employed
to account for patient acuity differences between the control and
NPWT samples. RESULTS: The commercial dataset yielded over
3500 patients meeting the study criteria while the Medicare
dataset included over 12,700 patients. This retrospective analy-
sis demonstrated that the proportion of patients with an ampu-
tation was lower following treatment with NPWT when
compared to the control group. This ﬁnding was consistent for
the commercial and Medicare datasets. From the commercial
dataset population, NPWT was associated with up to a 34%
lower amputation occurrence compared to the control group. 
(p = 0.09) In the Medicare population, the DFU risk-adjusted
amputation percentages were 16.6% for control and 10.8% for
NPWT groups (p = 0.007). Additionally, higher severity patients
(categorized based on debridement depth) experienced fewer
amputations when treated with NPWT vs. control therapies.
CONCLUSIONS: This retrospective analysis is the ﬁrst to assess
the relationship of NPWT to DFU amputations using two large
datasets. In this analysis, the results from two distinct datasets
consistently suggest that diabetic foot ulcer patients treated with
NPWT experienced a lower incidence of amputations compared
to control patients. NPWT may play an important role in the
incidence of diabetic-related amputation events that lead to sig-
niﬁcant economic and quality of life implications.
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OBJECTIVES: To determine the prevalence of diabetes, diabetes
control, and risk factors associated with type-2 diabetes control
in a sample of adult Latinos. METHODS: Data were obtained
from the Los Angeles Latino Eye Study (LALES), a large popu-
lation-based survey of eye disease in Latinos greater than 40
years of age including a clinical evaluation and home survey
questionnaire. All participants were stratiﬁed by diabetes status
and compared with non-diabetics. The participants with diabetes
were then stratiﬁed by diabetes control per the American Dia-
betes Association (ADA) guidelines. A multivariate logistic
regression analysis was conducted to identify risk factors asso-
ciated with diabetes control. The univariate and multivariate
analyses utilized components of the health behavior model,
which included predisposing, enabling and need characteristics.
RESULTS: Data for 6980 participants were evaluated. There
were 1321 participants identiﬁed with diabetes resulting in a
prevalence of 19%. Of all participants, 41.9% were males,
27.8% were single and 65.5% had insurance coverage. 3.8% of
the participants without a diabetes diagnosis had clinical values
(A1C) above the diabetic goal, indicating possible diabetes. Of
the diabetics, only 36% were controlled. Diabetics were older
(57.8 vs. 53.9; p < 0.0001) and insured (73.9% vs. 64.2%; p <
0.0001). 6.8% of the diabetics were untreated, 72.7% were
using oral anti-diabetic medication, 21.3% were using insulin,
57.4% were using diet and 15.3% were using a combination 
of oral medication and insulin. Logistic regression analysis 
(Likelihood X2 = 143.5, p < 0.0001) showed that lack of 
problems getting healthcare when needed, higher education,
lower Body Mass Index (BMI) and advancing age were associ-
ated with diabetes control. CONCLUSIONS: Though severity of
disease and medication adherence were not assessed, problems
getting care and a higher BMI were associated with poor dia-
betes control in this Latino population. While some diabetics in
this population are untreated, many are not meeting ADA goals
or remain undiagnosed.
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OBJECTIVES: Outcomes in patients with type 2 diabetes may
vary depending on the antidiabetic medication used. This study
compared differences in total health care costs, medication
adherence, and persistence in patients with type 2 diabetes
enrolled in the North Carolina Medicaid Program that were
newly started on thiazolidinedione (TZD) therapy with patients
starting other oral antidiabetics (OAD) during the same period.
METHODS: A total of 2660 patients newly starting TZD
therapy between July 2001 and December 2003 were compared
to 2050 patients starting other oral antidiabetic medication for
health care costs and outcomes in the post-medication start year.
Multivariate regression techniques incorporating health care uti-
lization in the year prior to start of new therapy were utilized to
determine the net cost impact of one therapy versus the other.
RESULTS: The mean age of the TZD group was signiﬁcantly
higher as compared to OAD group (p < 0.05). Total number of
prescription reﬁlls was signiﬁcantly higher with TZD than OAD
(p < 0.05). Other baseline characteristics were similar across the
two groups. The TZD cohort had signiﬁcantly higher persistence
rates as well as adherence rates compared to OAD in the 2nd
year (p < 0.01). Multiple regression analyses found that patients
starting TZD have better treatment persistence in the post-med-
ication start year compared to patients starting other oral antidi-
abetic agents. (4% increase in therapy persistence index, P <
0.001). In addition, patients starting TZDs had 19% lower total
